Drugs that contain Alogliptin Benzoate
1. Nesina patents expiration
Can you believe NESINA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(10 months from now) | |
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6211205 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6329404 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6150383 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6303640 | TAKEDA PHARMS USA | Pharmaceutical composition |
Aug, 2016
(7 years ago) | |
| US6303661 | TAKEDA PHARMS USA | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
| US7078381 | TAKEDA PHARMS USA | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US6890898 | TAKEDA PHARMS USA | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7459428 | TAKEDA PHARMS USA | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Dec, 2025
(1 year, 7 months from now) | |
| US8697125 | TAKEDA PHARMS USA | Tablet preparation without causing a tableting trouble |
Jun, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-300) | Jul 27, 2026 |
| M(M-177) | Apr 05, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Treatment: Methods of reducing the amount of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secr...
Dosage: TABLET;ORAL
How can I launch a generic of NESINA before it's drug patent expiration?
More Information on Dosage
NESINA family patents
